Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening
Open Access
- 1 October 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Infection and Drug Resistance
- Vol. ume 13, 3393-3399
- https://doi.org/10.2147/idr.s275152
Abstract
Purpose: With the easing of restriction measures, repeated community-based sampling for tracking new COVID-19 infections is anticipated for the next 6 to 12 months. A non-invasive, self-collected specimen like saliva will be useful for such public health surveillance. Investigations on the use of saliva for SARS-CoV-2 RT-PCR have largely been among COVID-19 in-pa\tients and symptomatic ambulatory patients with limited work in a community-based screening setting. This study was carried out to address this paucity of data and reported discrepancies in diagnostic accuracy for saliva samples. Patients and Methods: From 29th June to 14th July 2020, adults presenting for COVID-19 testing at a community-based screening facility in Dubai, United Arab Emirates were recruited. Clinical data, nasopharyngeal swab in universal transport media and drooling saliva in sterile containers were obtained. Reverse transcriptase PCR amplification of SARS-CoV-2 RdRp and N genes was used to detect the presence of the SARS-CoV-2 virus. Results: Of the 401 participants, 35 (8.7%) had viral detection in at least one specimen type and the majority (n=20/35; 57.1%) were asymptomatic. Both swab and saliva were positive in 19 (54.2%) patients, while 7 (20.0%) patients had swab positive/saliva negative results. There were 9 (25.7%) patients with saliva positive/swab negative result and this included 5 asymptomatic COVID-19 patients undergoing repeat screening. Using the swab as the reference gold standard, the sensitivity and specificity of saliva were 73.1% (95% CI 52.2– 88.4%) and 97.6% (95% CI 95.5– 98.9%) while the positive and negative predictive values were 67.9% (95% CI 51.5– 80.8%) and 98.1% (95% CI 96.5– 99.0%), respectively. Conclusion: The findings suggest good diagnostic accuracy for saliva and feasibility of utilization of specimen without transport media for SARS-CoV-2 RT-PCR. Saliva represents a potential specimen of choice in community settings and population-based screening.Keywords
This publication has 14 references indexed in Scilit:
- Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2Journal of Clinical Microbiology, 2020
- Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical SpecimensJournal of Clinical Microbiology, 2020
- Saliva is a reliable tool to detect SARS-CoV-2Journal of Infection, 2020
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort studyThe Lancet Infectious Diseases, 2020
- Viral dynamics in mild and severe cases of COVID-19The Lancet Infectious Diseases, 2020
- Detection of SARS-CoV-2 in Different Types of Clinical SpecimensJAMA, 2020
- Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity studyClinical Microbiology & Infection, 2018
- Additional molecular testing of saliva specimens improves the detection of respiratory virusesEmerging Microbes & Infections, 2017
- Requirements for Minimum Sample Size for Sensitivity and Specificity AnalysisJournal of Clinical and Diagnostic Research, 2016
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studiesBMJ, 2015